Skip to content
Annika Bansal – Lifestyle
Author:
Ensysce Biosciences
Ensysce Biosciences Phase 2 Protocol for CY200 – A Neuroplastigen for the Treatment of CRPS – Submitted to the UK MHRA
September 24, 2026
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
September 15, 2026
Ensysce Biosciences’ Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
September 14, 2026
DKS Investors with Losses in Excess of $100K Have Opportunity to Lead DICK’S Sporting Goods, Inc. Securities Fraud Lawsuit
September 9, 2026
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
September 2, 2026
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
August 31, 2026
MVST Deadline: MVST Investors with Losses in Excess of $100K Have Opportunity to Lead Microvast Holdings, Inc. Securities Fraud Lawsuit
August 28, 2026
WIX Deadline: WIX Investors with Losses in Excess of $100K Have Opportunity to Lead Wix.com Ltd. Securities Fraud Lawsuit
August 27, 2026
GPGI, CMPO Deadline: GPGI, CMPO Investors Have Opportunity to Lead GPGI, Inc. f/k/a CompoSecure, Inc. Securities Fraud Lawsuit
August 25, 2026
HTZ Deadline: HTZ Investors Have Opportunity to Lead Hertz Global Holdings, Inc. Securities Fraud Lawsuit
August 24, 2026
1
2
3
4
Next Page
→